|
|
-
Isis Pharmaceuticals Earns A $3.5 Mln Milestone Payment From Biogen Idec
5/9/2013
|
|
|
-
Isis Pharmaceuticals Prices Underwritten Public Offering Of 9 Mln Shares At $19/share
5/8/2013
|
|
|
-
Isis Pharmaceuticals Posts Q1 Loss Per Share Of $0.02 Vs. Loss $0.24 Year Ago
5/7/2013
|
-
Isis Pharmaceuticals Begins Phase 1b/2a Clinical Study Of ISIS-STAT3Rx In Patients With Advanced Metastatic HCC
5/6/2013
|
|
|
|
|
-
ISIS Pharma Says Begins Clinical Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy
4/23/2013
|